Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
NCT05586802 on ClinicalTrials.gov · last registry update 2026-05-11
A small phase 3 — 150 participants, against a typical 424. Due to report 30 April 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Design 1 : sperm retrieval rate at mTESE biopsy. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 21 March 2023 — 3 years so far.
- Status
- RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Georgios Papadakis
- Sponsor type
- Other
- Enrollment
- 150
- Started
- 2023-03-21
- Primary completion
- 2027-04-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Design 1 : sperm retrieval rate at mTESE biopsy
Conditions studied
Klinefelter Syndrome
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.